[A clinical study of prostatic carcinoma].
Seventy seven patients with prostatic carcinoma were treated in our clinic between 1977 and 1986. Most of them were treated by a hormonal agent as the first therapy. None of the 9 stage A1 cases showed any reactivation, but 4 of the 5 stage A2 cases relapsed to metastatic disease. The chemotherapy performed in 3 of the 4 reactivated cases had no obvious effect on the disease. Seven of the 8 patients with stage B disease were alive without relapse. Relapse was seen in the other patient who had poorly differentiated carcinoma and chemotherapy in this case resulted in stable disease for the present. Four of the 15 stage C cases including 3 poorly differentiated carcinomas were hormone resistant or reactivated. For these resistant cases radiotherapy and/or the chemotherapy were performed, but a response was seen in only one case. Consequently, the first therapy for stage A2, B and C of poorly differentiated carcinoma must be improved. Of the 40 stage D cases, 4 patients who were treated by an early combination of hormonal therapy and chemotherapy had a better prognosis than the others. These 4 patients had poorly differentiated carcinomas with multiple bone metastases. Two of these 4 patients were alive without relapse for 17 and 72 months, and one of the 2 patients with relapse was also alive for 75 months. We believe that early chemotherapy is the key for better prognosis in stage D cases.
Hashimoto
H
H
Department of Urology, Asahikawa Medical College.
Sasaki
M
M
Osanai
H
H
Inagaki
N
N
Yamauchi
K
K
Nishihara
M
M
Tokunaka
S
S
Yachiku
S
S
D000726:Androgen Antagonists / Q000627:therapeutic use; D002369:Castration; D003131:Combined Modality Therapy; D004961:Estramustine / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*
D000726:Androgen Antagonists; D004967:Estrogens; D004961:Estramustine